Growth & profitability
- Revenue has grown 19.4% per year over the past 5 years.
- Operating margin has expanded, at 9.8% in the latest year.
ACAD Financials Acadia Pharmaceuticals Inc
15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $1.1B | $391M | 91.7% | 9.8% | $105M | — | $178M |
| 2024 | $958M | $226M | 91.5% | 24.1% | $157M | — | $320M |
| 2023 | $726M | -$61M | 94.3% | -10.1% | $17M | — | $189M |
| 2022 | $517M | -$214M | 98.0% | -43.2% | -$114M | — | $115M |
| 2021 | $484M | -$168M | 97.8% | -35.2% | -$127M | — | $147M |
| 2020 | $442M | -$282M | 97.7% | -64.9% | -$144M | — | $326M |
| 2019 | $339M | -$235M | 96.7% | -72.7% | -$152M | — | $190M |
| 2018 | $224M | -$245M | 94.5% | -110.6% | -$170M | — | $135M |
| 2017 | $125M | -$289M | 92.7% | -234.1% | -$219M | — | $69M |
| 2016 | $17M | -$271M | 82.2% | -1574.1% | -$210M | — | $164M |
| 2015 | — | -$164M | — | — | — | — | $102M |
| 2014 | — | -$92M | — | — | — | — | $62M |
| 2013 | — | -$38M | — | — | — | — | $12M |
| 2012 | — | -$21M | — | — | — | — | $58M |
| 2011 | — | -$23M | — | — | -$20M | — | $7M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $268M | $4M | 90.8% | -1.7% | $29M | — | $282M |
| Dec '25 | $284M | $274M | 90.8% | 6.1% | -$53M | — | $178M |
| Sep '25 | $279M | $72M | 92.2% | 12.8% | $74M | — | $258M |
| Jun '25 | $265M | $27M | 92.2% | 12.2% | — | — | $254M |
| Mar '25 | $244M | $19M | 91.7% | 7.9% | $20M | — | $218M |
| Dec '24 | $260M | $144M | 91.6% | 59.1% | $40M | — | $320M |
| Sep '24 | $250M | $33M | 92.5% | 12.6% | $63M | — | $155M |
| Jun '24 | $242M | $33M | 92.5% | 12.6% | — | — | $177M |
| Mar '24 | $206M | $17M | 88.8% | 7.4% | — | — | $205M |
| Dec '23 | $231M | $46M | 92.3% | 15.1% | $85M | — | $189M |
| Sep '23 | $212M | -$65M | 93.1% | -27.3% | — | — | $98M |
| Jun '23 | $165M | $1M | 95.5% | 1.8% | — | — | $108M |
| Mar '23 | $118M | -$43M | 98.6% | -45.2% | — | — | $291M |
| Dec '22 | $136M | -$42M | 98.2% | -33.7% | -$24M | — | $115M |
| Sep '22 | $131M | -$27M | 98.4% | -23.6% | -$727000 | — | $155M |
| Jun '22 | $135M | -$34M | 98.0% | -25.0% | -$13M | — | $140M |
| Mar '22 | $115M | -$113M | 97.4% | -97.9% | -$76M | — | $205M |
| Dec '21 | $131M | -$43M | 98.1% | -34.2% | -$23M | — | $147M |
| Sep '21 | $132M | -$14M | 97.2% | -11.6% | -$17M | — | $95M |
| Jun '21 | $115M | -$44M | 97.8% | -37.9% | -$25M | — | $267M |
Valuation over time
How the market has priced ACAD against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has fallen from 13.9× (Dec '24) to 10.4× (Jun '26).
- The price-to-sales ratio has fallen from 6.2× (Mar '23) to 3.8× (Jun '26).
P/E
P/S
Frequently asked questions
Is ACAD growing its revenue and profit?
Over the past 5 years, Acadia Pharmaceuticals Inc's revenue has grown 19.4% per year. These are computed facts, not advice.
How much debt does ACAD have?
As of FY2025, Acadia Pharmaceuticals Inc reported — of total debt against $178M of cash.
What is ACAD's profit margin?
In FY2025, gross margin was 91.7%, operating margin 9.8%, and net margin 36.5%.
What is ACAD's P/E ratio?
As of Jun '26, Acadia Pharmaceuticals Inc traded at a price-to-earnings ratio of about 10.4× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.